Teva Pharmaceutical Industries Limited
As of Oct 23, 2026 close
- Market cap
- $45.91B
- P/E (TTM)
- 64.04
- Forward P/E
- -
- Dividend yield
- -
- 52-week range
- $18.83$42.02
- Volume (live)
- -
- Avg. volume (3M)
- 5.89M
Teva Pharmaceutical Industries (TEVA) Stock Price & Financial Analysis
Teva Pharmaceutical Industries Stock Price Chart
Loading chart...
Financial Metrics & Key Statistics
Fundamental metrics, valuation ratios, and profitability indicators
| Day's Range | $39.11 - $39.84 |
|---|---|
| 52-Week High | $42.02 |
| 52-Week Low | $18.83 |
| Open | $39.75 |
| Volume (last close) | 5.60M |
| Average Volume (3M) | 5.89M |
| Revenue (TTM) | 17.40B |
|---|---|
| Net Income (TTM) | 716.92M |
| Free Cash Flow (TTM) | 2.38B |
| EPS (TTM) | $0.61 |
| Profit Margin | 4.12% |
| Operating Margin | 14.92% |
| Return on Equity (ROE) | 9.25% |
| Debt to Equity | 2.17 |
| Annual Dividend | $0.00 |
|---|---|
| Dividend Yield | 0.00% |
| Payout Ratio | 0.00% |
| Last Dividend Ex-Date | Nov 27, 2017 |
| Market Cap | 45.91B |
|---|---|
| Shares Outstanding | 1.17B |
| P/E Ratio (TTM) | 64.04 |
| Price to Sales (P/S) | 2.64 |
| Price to Book (P/B) | 5.92 |
| EV/EBITDA | 19.49 |
| 50-Day MA | $38.48 |
|---|---|
| 200-Day MA | $34.25 |
| 1-Year Change | +111.41% |
Source: Market prices and company fundamentals. Data as of Oct 23, 2026. Data sources and methodology
Teva Pharmaceutical Industries at a Glance
As of the Oct 23, 2026 close, Teva Pharmaceutical Industries (TEVA) has a market capitalization of $45.91B. The stock trades at 64.0× trailing earnings and 2.6× sales. Over the trailing twelve months it earned $716.92M on revenue of $17.40B (a 4.1% profit margin) and generated $2.38B of free cash flow. Revenue grew 4.7% year over year.
As of its latest reported balance sheet, it holds $3.63B in cash and securities against $16.84B of debt, a net debt position of $13.21B.
Teva Pharmaceutical Industries does not currently pay a dividend.
The share price is up 111.4% over the past year. At $39.41 (the Oct 23, 2026 close) it sits near the top of its 52-week range of $18.82 to $42.02, above its 200-day moving average of $34.25.
Based on 10 professional analyst ratings from the past 90 days, the consensus is Buy with an average price target of $48.39, 22.8% above the Oct 23, 2026 close.
Frequently Asked Questions About Teva Pharmaceutical Industries
What is the current stock price for TEVA?
As of the Oct 23, 2026 close, TEVA stock trades at $39.41. The 52-week range is $18.83–$42.02, with a day range of $39.11–$39.84.
What is the P/E ratio for TEVA?
As of the Oct 23, 2026 close, Teva Pharmaceutical Industries's trailing twelve-month (TTM) P/E ratio is 64.0, meaning investors pay $64.0 for every $1 of annual earnings. Teva Pharmaceutical Industries operates in the Healthcare sector.
Does TEVA pay dividends?
Teva Pharmaceutical Industries does not currently pay a regular dividend. The company retains its earnings to reinvest in the business. Check the Dividends tab for historical dividend information.
What do analysts recommend for TEVA?
Based on ratings from 10 professional analysts over the last 90 days, the consensus for TEVA is Buy. The average 12-month price target is $48.39, a 22.8% upside from the Oct 23, 2026 close of $39.41.
What is the market cap of TEVA?
As of the Oct 23, 2026 close, Teva Pharmaceutical Industries's market capitalization is $45.91B, classifying it as a large-cap company. Teva Pharmaceutical Industries operates in the Healthcare sector within the Drug Manufacturers - Specialty & Generic industry.